Direxion Daily SP Biotech Bear 3X Shares Equity-NMS: LABD

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$6.88
Open :	$6.8
Today's high :	$7.12
Today's low :	$6.73
52W low :	$4.6599
52W high :	$16.05
1Y :	-3.13%
5Y :	-93.56%

What is Direxion Daily SP Biotech Bear 3X Shares (LABD) price today?

The Direxion Daily SP Biotech Bear 3X Shares (LABD) share price as of June 10, 2025 is $7.11. If you are investing from India, you can check the value in INR before investing.

Can I buy Direxion Daily SP Biotech Bear 3X Shares (LABD) shares?

Yes, Indian investors can buy Direxion Daily SP Biotech Bear 3X Shares (LABD) in the US stock market by opening an International Trading Account with Angel One.

How to buy Direxion Daily SP Biotech Bear 3X Shares (LABD) Shares in India?

Indian investors can buy Direxion Daily SP Biotech Bear 3X Shares (LABD) through the following modes:

Direct investment: One can invest through opening an International Trading Account with Angel One. Once account is opened, you can add funds in U.S. dollars to buy Direxion Daily SP Biotech Bear 3X Shares (LABD).
Indirect investment: One can invest indirectly in Direxion Daily SP Biotech Bear 3X Shares (LABD) through mutual funds and Exchange Traded Funds (ETFs) that offer exposure to global stocks.

Can I buy Fractional shares of Direxion Daily SP Biotech Bear 3X Shares (LABD)?

Yes, you can buy a fraction of Direxion Daily SP Biotech Bear 3X Shares (LABD). In Angel One, you can buy global stocks for any dollar value.

The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.